Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors

Current Eye Research

Volumn 37, Issue 5, 2012, Pages 399-407

  Myers, Anna Cardiakidis ^a   Lövestam Adrian, Monica ^a   Bruun, Anitha ^a   Ghosh, Fredrik ^a   Andréasson, Sten ^a   Ponjavic, Vesna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bevacizumab; Drug toxicity; Electrophysiology; Electroretinography; Histopathology; Pegaptanib; Ranibizumab

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ELECTRORETINOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MULTIFOCAL ELECTRORETINOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA CONE; RETINA HORIZONTAL NERVE CELL; RETINA ROD; RETINOPATHY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; RABBITS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859906379     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.611609     Document Type: Article

References (44)

1. Wong TY, Wong T, Chakravarthy U et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116-126.
2. Schmidt-Erfurth UM, Richard G, Augustin A et al.; European Society for Retina Specialists' Guidelines Committee (EURETINA). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486-494. (Pubitemid 47163109)
3. Sim R, Hernndez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574-1580.
4. Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518-522. (Pubitemid 351497981)
5. Kreutzer TC, Alge CS, Wolf AH et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351-355. (Pubitemid 351363529)
6. Michelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for central retinal diseases. Eye. 1948:136-180.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
8. Marneros AG, Fan J, Yokoyama Y et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167:1451-1459. (Pubitemid 41541430)
9. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008;22:1330-1336.
10. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49: 4523-4527.
11. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem. 2007;7:223-245. (Pubitemid 46403586)
12. Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1837-1842. (Pubitemid 350154019)
13. Ip MS, Scott IU, Brown GC et al.; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837-1846.
14. Patel PJ, Bunce C, Tufail A; ABC Trial Investigators. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials. 2008;9:56.
15. Ziemssen F, Lake M, Messias A et al.; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol. 2008;28:101-109.
16. Peters S, Heiduschka P, Julien S et al. Tabingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007;143:995-1002.
17. Heiduschka P, Fietz H, Hofmeister S et al.; Tabingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823. (Pubitemid 351261238)
18. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91:1230-1233. (Pubitemid 47344905)
19. Saint-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on maller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
20. Stahl A, Feltgen N, Fuchs A, Bach M. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol. 2009;118:81-88.
21. Maier M, Feucht N, Lanzi I, Kook. P, Lohmann CP. Retinochoroidopathy after intravitreal anti-VEGF treatment. Ophthalmologe. 2008.doi:10.1007/s00347- 008-1839-3
22. Lipski A, Bornfeld N, Jurklies B. Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium. Retina (Philadelphia, Pa). 2007;27:864-872. (Pubitemid 47479381)
23. Pedersen KB, Mller F, Sjalie AK, Andraasson S. Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina (Philadelphia, Pa). 2010;30:1025-1033.
24. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118:176-183.
25. Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450-1455.
26. Tasman W, Jaeger EA (Eds.). Duane's foundations of clinical ophthalmology. Vol 1., Chap 16. Philadelphia, PA: Lippincott Williams & Wilkins, 1998.
27. Larsen JS. The sagittal growth of the eye. 3. Ultrasonic measurement of the posterior segment (axial length of the vitreous) from birth to puberty. Acta Ophthalmol (Copenh). 1971;49:441-453.
28. Prince JH: The vitreous. In: Prince JH (Ed.) The Rabbit in Eye Research. Springfield, Charles C Thomas, 1964; pp. 372-384.
29. Gjarloff K, Andrasson S, Ehinger B. Standardized fullfield electroretinography in rabbits. Doc Ophthalmol. 2004; 109:163-168.
30. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69-77.
31. Gjarloff KW, Andrasson S, Ghosh F. mfERG in normal and lesioned rabbit retina. Graefes Arch Clin Exp Ophthalmol. 2006;244:83-89.
32. Heilweil G, Komarowska I, Zemel E, Loewenstein A, Perlman I. Normal physiological and pathophysiological effects of trypan blue on the retinas of albino rabbits. Invest Ophthalmol Vis Sci. 2010;51:4187-4194.
33. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (Philadelphia, Pa). 2006;26:262-269. (Pubitemid 44318177)
34. Koistinaho J, Sagar SM. Localization of protein kinase C subspecies in the rabbit retina. Neurosci Lett. 1994;177:15-18. (Pubitemid 24269418)
35. Wood JP, McCord RJ, Osborne NN. Retinal protein kinase C. Neurochem Int. 1997;30:119-136.
36. Blanks JC, Johnson LV. Specific binding of peanut lectin to a class of retinal photoreceptor cells. A species comparison. Invest Ophthalmol Vis Sci. 1984;25:546-557. (Pubitemid 14149146)
37. Casini G, Rickman DW, Brecha NC. AII amacrine cell population in the rabbit retina: identification by parvalbumin immunoreactivity. J Comp Neurol. 1995;356:132-142.
38. MacKenzie D, Arendt A, Hargrave P, McDowell JH, Molday RS. Localization of binding sites for carboxyl terminal specific anti-rhodopsin monoclonal antibodies using synthetic peptides. Biochemistry. 1984;23:6544-6549.
39. Massey SC, Mills SL. A calbindin-immunoreactive cone bipolar cell type in the rabbit retina. J Comp Neurol. 1996;366: 15-33. (Pubitemid 26069266)
40. Wu WC, Lai CC, Chen KJ et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci. 2010;51:3701-3708.
41. Arraes JC, Tedesco RC, Arraes TA, Silva EB, Ventura A, Avila MP. Intravitreal bevacizumab in pigmented rabbit eyes: histological analysis 90 days after injection. Arq Bras Oftalmol. 2009;72:656-660.
42. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol. 2009;247:1601-1608.
43. Hood DC, Birch DG. Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. J Opt Soc Am A Opt Image Sci Vis. 1996;13:623-633. (Pubitemid 126542173)
44. Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018-2026. (Pubitemid 26376289)